These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17330787)

  • 1. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
    Barreiro P; Rodríguez-Novoa S; Labarga P; Ruiz A; Jiménez-Nácher I; Martín-Carbonero L; Gonzalez-Lahoz J; Soriano V
    J Infect Dis; 2007 Apr; 195(7):973-9. PubMed ID: 17330787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
    Slish J; Ma Q; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau D; Boston NS; Catanzaro L; DiFrancesco R; Morse GD
    Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
    Poirier JM; Robidou P; Jaillon P
    Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
    Edén A; Andersson LM; Andersson O; Flamholc L; Josephson F; Nilsson S; Ormaasen V; Svedhem V; Säll C; Sönnerborg A; Tunbäck P; Gisslén M
    AIDS Res Hum Retroviruses; 2010 May; 26(5):533-40. PubMed ID: 20455766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
    Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
    Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.
    Winzer R; Langmann P; Zilly M; Tollmann F; Schubert J; Klinker H; Weissbrich B
    Eur J Med Res; 2003 Dec; 8(12):531-4. PubMed ID: 14711599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
    Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
    Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
    Dominguez S; Ghosn J; Peytavin G; Guiguet M; Tubiana R; Valantin MA; Murphy R; Bricaire F; Benhamou Y; Katlama C
    J Antimicrob Chemother; 2010 Nov; 65(11):2445-9. PubMed ID: 20813809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
    Schoenenberger JA; Aragones AM; Cano SM; Puig T; Castello A; Gomez-Arbones X; Porcel JM
    Ther Drug Monit; 2013 Feb; 35(1):71-7. PubMed ID: 23188184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
    Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C.
    Meynard JL; Lacombe K; Poirier JM; Legrand J; Morand-Joubert L; Girard PM
    J Antimicrob Chemother; 2009 Mar; 63(3):579-84. PubMed ID: 19168543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C.
    Rivero-Juarez A; Mira JA; Santos-Gil I; Lopez-Cortes LF; Girón-Gonzalez JA; Marquez M; Merino D; Tellez F; Caruz A; Pineda JA; Rivero A;
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):223-5. PubMed ID: 22966845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.